MOLECL

Currently, detection of protein modifications like glycosylation is slow, expensive, and often lacks site-specific resolution. This leads to late-stage diagnostics in cancer, neurodegenerative, and autoimmune diseases, as well as batch-to-batch variations in biopharmaceutical production. Today, these issues result in approximately 50 billion CHF in losses each year. New analytical tools are urgently needed to close this gap.
We develop nanopore-based detection of protein modifications, combining solid-state nanopores and affinity assays for site-specific PTM analysis. The founders are experts in solid-state nanopores and start-up development, supported by a tech team specializing in single-molecule measurements and data science. We work directly with stakeholders to deliver the solution.